nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—CYP2D6—breast cancer	0.271	1	CbGaD
Zuclopenthixol—HTR6—Raloxifene—breast cancer	0.166	0.613	CbGbCtD
Zuclopenthixol—CYP2D6—Idarubicin—breast cancer	0.0435	0.16	CbGbCtD
Zuclopenthixol—CYP2D6—Vinorelbine—breast cancer	0.0212	0.0782	CbGbCtD
Zuclopenthixol—CYP2D6—Tamoxifen—breast cancer	0.0192	0.0706	CbGbCtD
Zuclopenthixol—CYP2D6—Vinblastine—breast cancer	0.0131	0.0482	CbGbCtD
Zuclopenthixol—CYP2D6—Doxorubicin—breast cancer	0.00804	0.0296	CbGbCtD
Zuclopenthixol—Trifluoperazine—S100A4—breast cancer	0.00135	0.237	CrCbGaD
Zuclopenthixol—Hydroxyzine—CYP2D6—breast cancer	0.00028	0.0492	CrCbGaD
Zuclopenthixol—Flupentixol—ABCB1—breast cancer	0.000192	0.0336	CrCbGaD
Zuclopenthixol—Clozapine—CYP1B1—breast cancer	0.000186	0.0327	CrCbGaD
Zuclopenthixol—Domperidone—CYP2D6—breast cancer	0.000181	0.0317	CrCbGaD
Zuclopenthixol—Domperidone—CYP3A4—breast cancer	0.000155	0.0272	CrCbGaD
Zuclopenthixol—Nefazodone—CYP2D6—breast cancer	0.00015	0.0263	CrCbGaD
Zuclopenthixol—Trazodone—CYP2D6—breast cancer	0.000139	0.0243	CrCbGaD
Zuclopenthixol—DRD5—female reproductive system—breast cancer	0.000131	0.0635	CbGeAlD
Zuclopenthixol—Thiothixene—CYP2D6—breast cancer	0.00013	0.0228	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP2D6—breast cancer	0.00013	0.0228	CrCbGaD
Zuclopenthixol—Domperidone—ABCB1—breast cancer	0.000129	0.0226	CrCbGaD
Zuclopenthixol—Nefazodone—CYP3A4—breast cancer	0.000129	0.0226	CrCbGaD
Zuclopenthixol—Chlorpromazine—BCHE—breast cancer	0.000128	0.0225	CrCbGaD
Zuclopenthixol—Prochlorperazine—CYP2D6—breast cancer	0.000124	0.0218	CrCbGaD
Zuclopenthixol—Trazodone—CYP3A4—breast cancer	0.000119	0.0209	CrCbGaD
Zuclopenthixol—DRD5—female gonad—breast cancer	0.000119	0.0578	CbGeAlD
Zuclopenthixol—Amoxapine—CYP2D6—breast cancer	0.000114	0.0201	CrCbGaD
Zuclopenthixol—Fluphenazine—CYP2D6—breast cancer	0.000112	0.0197	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP3A4—breast cancer	0.000112	0.0196	CrCbGaD
Zuclopenthixol—DRD5—endocrine gland—breast cancer	0.00011	0.0538	CbGeAlD
Zuclopenthixol—Nefazodone—ABCB1—breast cancer	0.000107	0.0188	CrCbGaD
Zuclopenthixol—Prochlorperazine—CYP3A4—breast cancer	0.000107	0.0187	CrCbGaD
Zuclopenthixol—Clozapine—CYP1A1—breast cancer	0.000101	0.0177	CrCbGaD
Zuclopenthixol—Trazodone—ABCB1—breast cancer	9.91e-05	0.0174	CrCbGaD
Zuclopenthixol—Thioproperazine—ALB—breast cancer	9.89e-05	0.0173	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—breast cancer	9.73e-05	0.0171	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—breast cancer	9.73e-05	0.0171	CrCbGaD
Zuclopenthixol—Thioridazine—CYP2D6—breast cancer	9.68e-05	0.017	CrCbGaD
Zuclopenthixol—HRH1—nipple—breast cancer	9.3e-05	0.0453	CbGeAlD
Zuclopenthixol—ADRA2A—nipple—breast cancer	9.14e-05	0.0445	CbGeAlD
Zuclopenthixol—Perphenazine—CYP2D6—breast cancer	8.88e-05	0.0156	CrCbGaD
Zuclopenthixol—Quetiapine—CYP2D6—breast cancer	8.71e-05	0.0153	CrCbGaD
Zuclopenthixol—ADRA1A—epithelium—breast cancer	8.09e-05	0.0394	CbGeAlD
Zuclopenthixol—Fluphenazine—ABCB1—breast cancer	8.02e-05	0.0141	CrCbGaD
Zuclopenthixol—Perphenazine—CYP3A4—breast cancer	7.62e-05	0.0134	CrCbGaD
Zuclopenthixol—Rash—Mitoxantrone—breast cancer	7.55e-05	0.000217	CcSEcCtD
Zuclopenthixol—Rash—Irinotecan—breast cancer	7.55e-05	0.000217	CcSEcCtD
Zuclopenthixol—Dermatitis—Irinotecan—breast cancer	7.54e-05	0.000217	CcSEcCtD
Zuclopenthixol—Dermatitis—Mitoxantrone—breast cancer	7.54e-05	0.000217	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—breast cancer	7.54e-05	0.000217	CcSEcCtD
Zuclopenthixol—Headache—Mitoxantrone—breast cancer	7.5e-05	0.000216	CcSEcCtD
Zuclopenthixol—Headache—Irinotecan—breast cancer	7.5e-05	0.000216	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2D6—breast cancer	7.49e-05	0.0132	CrCbGaD
Zuclopenthixol—Hypotension—Capecitabine—breast cancer	7.49e-05	0.000215	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—breast cancer	7.49e-05	0.000215	CcSEcCtD
Zuclopenthixol—Quetiapine—CYP3A4—breast cancer	7.47e-05	0.0131	CrCbGaD
Zuclopenthixol—Paraesthesia—Docetaxel—breast cancer	7.43e-05	0.000214	CcSEcCtD
Zuclopenthixol—Vomiting—Gemcitabine—breast cancer	7.42e-05	0.000213	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—breast cancer	7.38e-05	0.000212	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—breast cancer	7.36e-05	0.000212	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—breast cancer	7.36e-05	0.000212	CcSEcCtD
Zuclopenthixol—Rash—Gemcitabine—breast cancer	7.36e-05	0.000211	CcSEcCtD
Zuclopenthixol—Dermatitis—Gemcitabine—breast cancer	7.35e-05	0.000211	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—breast cancer	7.35e-05	0.000211	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—breast cancer	7.33e-05	0.000211	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—breast cancer	7.31e-05	0.00021	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—breast cancer	7.31e-05	0.00021	CcSEcCtD
Zuclopenthixol—Headache—Gemcitabine—breast cancer	7.31e-05	0.00021	CcSEcCtD
Zuclopenthixol—Chlorprothixene—ABCB1—breast cancer	7.31e-05	0.0128	CrCbGaD
Zuclopenthixol—Musculoskeletal discomfort—Capecitabine—breast cancer	7.3e-05	0.00021	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—breast cancer	7.3e-05	0.00021	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—breast cancer	7.29e-05	0.00021	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—breast cancer	7.29e-05	0.000209	CcSEcCtD
Zuclopenthixol—Insomnia—Capecitabine—breast cancer	7.25e-05	0.000208	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—breast cancer	7.23e-05	0.000208	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—breast cancer	7.23e-05	0.000208	CcSEcCtD
Zuclopenthixol—Paraesthesia—Capecitabine—breast cancer	7.2e-05	0.000207	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—breast cancer	7.2e-05	0.000207	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Paclitaxel—breast cancer	7.2e-05	0.000207	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—breast cancer	7.19e-05	0.000207	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—breast cancer	7.18e-05	0.000206	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—breast cancer	7.16e-05	0.000206	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—breast cancer	7.15e-05	0.000205	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—breast cancer	7.15e-05	0.000205	CcSEcCtD
Zuclopenthixol—Dyspnoea—Capecitabine—breast cancer	7.15e-05	0.000205	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—breast cancer	7.14e-05	0.000205	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—breast cancer	7.13e-05	0.000205	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—breast cancer	7.13e-05	0.000205	CcSEcCtD
Zuclopenthixol—Nausea—Mitoxantrone—breast cancer	7.11e-05	0.000205	CcSEcCtD
Zuclopenthixol—Nausea—Irinotecan—breast cancer	7.11e-05	0.000205	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—breast cancer	7.1e-05	0.000204	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—breast cancer	7.08e-05	0.000204	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—breast cancer	7.08e-05	0.000204	CcSEcCtD
Zuclopenthixol—Dyspepsia—Capecitabine—breast cancer	7.06e-05	0.000203	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP2D6—breast cancer	7.05e-05	0.0124	CrCbGaD
Zuclopenthixol—Arrhythmia—Epirubicin—breast cancer	7.02e-05	0.000202	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—breast cancer	7.01e-05	0.000201	CcSEcCtD
Zuclopenthixol—Asthenia—Paclitaxel—breast cancer	7.01e-05	0.000201	CcSEcCtD
Zuclopenthixol—Decreased appetite—Capecitabine—breast cancer	6.97e-05	0.0002	CcSEcCtD
Zuclopenthixol—Nausea—Gemcitabine—breast cancer	6.93e-05	0.000199	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Capecitabine—breast cancer	6.92e-05	0.000199	CcSEcCtD
Zuclopenthixol—Fatigue—Capecitabine—breast cancer	6.91e-05	0.000199	CcSEcCtD
Zuclopenthixol—Pruritus—Paclitaxel—breast cancer	6.91e-05	0.000199	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—breast cancer	6.89e-05	0.000198	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—breast cancer	6.89e-05	0.000198	CcSEcCtD
Zuclopenthixol—Pain—Capecitabine—breast cancer	6.86e-05	0.000197	CcSEcCtD
Zuclopenthixol—Constipation—Capecitabine—breast cancer	6.86e-05	0.000197	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—breast cancer	6.84e-05	0.000197	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—breast cancer	6.84e-05	0.000197	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Docetaxel—breast cancer	6.82e-05	0.000196	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—breast cancer	6.81e-05	0.000196	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—breast cancer	6.8e-05	0.000195	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—breast cancer	6.78e-05	0.000195	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—breast cancer	6.78e-05	0.000195	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—breast cancer	6.77e-05	0.000195	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—breast cancer	6.75e-05	0.000194	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—breast cancer	6.74e-05	0.000194	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—breast cancer	6.71e-05	0.000193	CcSEcCtD
Zuclopenthixol—Diarrhoea—Paclitaxel—breast cancer	6.68e-05	0.000192	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—breast cancer	6.65e-05	0.000191	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Capecitabine—breast cancer	6.61e-05	0.00019	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—breast cancer	6.6e-05	0.00019	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—breast cancer	6.59e-05	0.00019	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—breast cancer	6.57e-05	0.000189	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—breast cancer	6.57e-05	0.000189	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Capecitabine—breast cancer	6.56e-05	0.000188	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—breast cancer	6.55e-05	0.000188	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—breast cancer	6.55e-05	0.000188	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—breast cancer	6.54e-05	0.000188	CcSEcCtD
Zuclopenthixol—ADRA1A—adipose tissue—breast cancer	6.54e-05	0.0318	CbGeAlD
Zuclopenthixol—Arrhythmia—Doxorubicin—breast cancer	6.5e-05	0.000187	CcSEcCtD
Zuclopenthixol—Dizziness—Paclitaxel—breast cancer	6.46e-05	0.000186	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—breast cancer	6.45e-05	0.000185	CcSEcCtD
Zuclopenthixol—DRD2—pituitary gland—breast cancer	6.44e-05	0.0313	CbGeAlD
Zuclopenthixol—Clozapine—CYP3A4—breast cancer	6.43e-05	0.0113	CrCbGaD
Zuclopenthixol—Trifluoperazine—ABCB1—breast cancer	6.41e-05	0.0113	CrCbGaD
Zuclopenthixol—HTR2A—embryo—breast cancer	6.41e-05	0.0312	CbGeAlD
Zuclopenthixol—Mental disorder—Doxorubicin—breast cancer	6.37e-05	0.000183	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—breast cancer	6.35e-05	0.000182	CcSEcCtD
Zuclopenthixol—Body temperature increased—Capecitabine—breast cancer	6.34e-05	0.000182	CcSEcCtD
Zuclopenthixol—Abdominal pain—Capecitabine—breast cancer	6.34e-05	0.000182	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—breast cancer	6.34e-05	0.000182	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—breast cancer	6.33e-05	0.000182	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—breast cancer	6.33e-05	0.000182	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—breast cancer	6.29e-05	0.000181	CcSEcCtD
Zuclopenthixol—HRH1—epithelium—breast cancer	6.26e-05	0.0305	CbGeAlD
Zuclopenthixol—Flatulence—Doxorubicin—breast cancer	6.24e-05	0.000179	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—breast cancer	6.22e-05	0.000179	CcSEcCtD
Zuclopenthixol—Quetiapine—ABCB1—breast cancer	6.22e-05	0.0109	CrCbGaD
Zuclopenthixol—Tension—Doxorubicin—breast cancer	6.21e-05	0.000179	CcSEcCtD
Zuclopenthixol—Vomiting—Paclitaxel—breast cancer	6.21e-05	0.000179	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.18e-05	0.000178	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—breast cancer	6.17e-05	0.000177	CcSEcCtD
Zuclopenthixol—Rash—Paclitaxel—breast cancer	6.16e-05	0.000177	CcSEcCtD
Zuclopenthixol—Dermatitis—Paclitaxel—breast cancer	6.15e-05	0.000177	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—breast cancer	6.15e-05	0.000177	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—breast cancer	6.15e-05	0.000177	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—breast cancer	6.15e-05	0.000177	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—breast cancer	6.14e-05	0.000176	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—breast cancer	6.13e-05	0.000176	CcSEcCtD
Zuclopenthixol—Headache—Paclitaxel—breast cancer	6.12e-05	0.000176	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—breast cancer	6.1e-05	0.000175	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—breast cancer	6.05e-05	0.000174	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP3A4—breast cancer	6.05e-05	0.0106	CrCbGaD
Zuclopenthixol—Loss of consciousness—Epirubicin—breast cancer	6.01e-05	0.000173	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—breast cancer	5.97e-05	0.000172	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—breast cancer	5.97e-05	0.000172	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—breast cancer	5.94e-05	0.000171	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—breast cancer	5.93e-05	0.00017	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—breast cancer	5.91e-05	0.00017	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Capecitabine—breast cancer	5.91e-05	0.00017	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—breast cancer	5.87e-05	0.000169	CcSEcCtD
Zuclopenthixol—ADRA1A—adrenal gland—breast cancer	5.87e-05	0.0286	CbGeAlD
Zuclopenthixol—Pruritus—Docetaxel—breast cancer	5.86e-05	0.000168	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—breast cancer	5.85e-05	0.000168	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—breast cancer	5.84e-05	0.000168	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—breast cancer	5.83e-05	0.000167	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—breast cancer	5.82e-05	0.000167	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—breast cancer	5.81e-05	0.000167	CcSEcCtD
Zuclopenthixol—Nausea—Paclitaxel—breast cancer	5.8e-05	0.000167	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—breast cancer	5.8e-05	0.000167	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.79e-05	0.000166	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—breast cancer	5.77e-05	0.000166	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—breast cancer	5.76e-05	0.000165	CcSEcCtD
Zuclopenthixol—Asthenia—Capecitabine—breast cancer	5.75e-05	0.000165	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—breast cancer	5.71e-05	0.000164	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—breast cancer	5.7e-05	0.000164	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—breast cancer	5.69e-05	0.000164	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—breast cancer	5.69e-05	0.000164	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—breast cancer	5.68e-05	0.000163	CcSEcCtD
Zuclopenthixol—Pruritus—Capecitabine—breast cancer	5.67e-05	0.000163	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—breast cancer	5.67e-05	0.000163	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—breast cancer	5.66e-05	0.000163	CcSEcCtD
Zuclopenthixol—HRH1—endometrium—breast cancer	5.62e-05	0.0273	CbGeAlD
Zuclopenthixol—Palpitations—Doxorubicin—breast cancer	5.6e-05	0.000161	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—breast cancer	5.58e-05	0.000161	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—breast cancer	5.58e-05	0.00016	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—breast cancer	5.56e-05	0.00016	CcSEcCtD
Zuclopenthixol—ADRA2A—endometrium—breast cancer	5.52e-05	0.0269	CbGeAlD
Zuclopenthixol—Shock—Epirubicin—breast cancer	5.49e-05	0.000158	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—breast cancer	5.49e-05	0.000158	CcSEcCtD
Zuclopenthixol—Diarrhoea—Capecitabine—breast cancer	5.48e-05	0.000158	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—breast cancer	5.48e-05	0.000157	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—breast cancer	5.48e-05	0.000157	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—breast cancer	5.47e-05	0.000157	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—breast cancer	5.47e-05	0.000157	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—breast cancer	5.45e-05	0.000157	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—breast cancer	5.44e-05	0.000156	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—breast cancer	5.42e-05	0.000156	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—breast cancer	5.4e-05	0.000155	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—breast cancer	5.4e-05	0.000155	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—breast cancer	5.39e-05	0.000155	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—breast cancer	5.37e-05	0.000154	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—breast cancer	5.36e-05	0.000154	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.35e-05	0.000154	CcSEcCtD
Zuclopenthixol—Clozapine—ABCB1—breast cancer	5.35e-05	0.00939	CrCbGaD
Zuclopenthixol—Discomfort—Doxorubicin—breast cancer	5.33e-05	0.000153	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—breast cancer	5.32e-05	0.000153	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—breast cancer	5.32e-05	0.000153	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—breast cancer	5.31e-05	0.000152	CcSEcCtD
Zuclopenthixol—Dizziness—Capecitabine—breast cancer	5.3e-05	0.000152	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ALB—breast cancer	5.27e-05	0.00925	CrCbGaD
Zuclopenthixol—Dry mouth—Doxorubicin—breast cancer	5.27e-05	0.000152	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—breast cancer	5.26e-05	0.000151	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—breast cancer	5.25e-05	0.000151	CcSEcCtD
Zuclopenthixol—HTR2A—epithelium—breast cancer	5.23e-05	0.0255	CbGeAlD
Zuclopenthixol—Rash—Docetaxel—breast cancer	5.22e-05	0.00015	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—breast cancer	5.22e-05	0.00015	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—breast cancer	5.22e-05	0.00015	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—breast cancer	5.19e-05	0.000149	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—breast cancer	5.19e-05	0.000149	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—breast cancer	5.17e-05	0.000149	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—breast cancer	5.15e-05	0.000148	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—breast cancer	5.14e-05	0.000148	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—breast cancer	5.1e-05	0.000147	CcSEcCtD
Zuclopenthixol—Vomiting—Capecitabine—breast cancer	5.1e-05	0.000147	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—breast cancer	5.09e-05	0.000146	CcSEcCtD
Zuclopenthixol—ADRA1A—endocrine gland—breast cancer	5.09e-05	0.0248	CbGeAlD
Zuclopenthixol—ADRA2A—uterus—breast cancer	5.09e-05	0.0248	CbGeAlD
Zuclopenthixol—Shock—Doxorubicin—breast cancer	5.08e-05	0.000146	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—breast cancer	5.07e-05	0.000146	CcSEcCtD
Zuclopenthixol—HRH1—adipose tissue—breast cancer	5.06e-05	0.0246	CbGeAlD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—breast cancer	5.06e-05	0.000145	CcSEcCtD
Zuclopenthixol—Rash—Capecitabine—breast cancer	5.05e-05	0.000145	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—breast cancer	5.05e-05	0.000145	CcSEcCtD
Zuclopenthixol—Dermatitis—Capecitabine—breast cancer	5.05e-05	0.000145	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—breast cancer	5.04e-05	0.000145	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ABCB1—breast cancer	5.03e-05	0.00883	CrCbGaD
Zuclopenthixol—Headache—Capecitabine—breast cancer	5.02e-05	0.000144	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—breast cancer	5.02e-05	0.000144	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—breast cancer	5.01e-05	0.000144	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—breast cancer	5e-05	0.000144	CcSEcCtD
Zuclopenthixol—ADRA2A—pituitary gland—breast cancer	4.99e-05	0.0243	CbGeAlD
Zuclopenthixol—DRD2—endocrine gland—breast cancer	4.99e-05	0.0243	CbGeAlD
Zuclopenthixol—Dyspnoea—Epirubicin—breast cancer	4.98e-05	0.000143	CcSEcCtD
Zuclopenthixol—ADRA2A—adipose tissue—breast cancer	4.97e-05	0.0242	CbGeAlD
Zuclopenthixol—Somnolence—Epirubicin—breast cancer	4.96e-05	0.000143	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—breast cancer	4.93e-05	0.000142	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—breast cancer	4.92e-05	0.000141	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—breast cancer	4.92e-05	0.000141	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—breast cancer	4.92e-05	0.000141	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—breast cancer	4.88e-05	0.00014	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—breast cancer	4.85e-05	0.00014	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—breast cancer	4.83e-05	0.000139	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—breast cancer	4.82e-05	0.000139	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—breast cancer	4.81e-05	0.000138	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—breast cancer	4.78e-05	0.000137	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—breast cancer	4.78e-05	0.000137	CcSEcCtD
Zuclopenthixol—Nausea—Capecitabine—breast cancer	4.76e-05	0.000137	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—breast cancer	4.72e-05	0.000136	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—breast cancer	4.72e-05	0.000136	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.71e-05	0.000135	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—breast cancer	4.67e-05	0.000134	CcSEcCtD
Zuclopenthixol—HRH1—female reproductive system—breast cancer	4.65e-05	0.0227	CbGeAlD
Zuclopenthixol—Paraesthesia—Doxorubicin—breast cancer	4.64e-05	0.000133	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—breast cancer	4.61e-05	0.000132	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—breast cancer	4.6e-05	0.000132	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—breast cancer	4.59e-05	0.000132	CcSEcCtD
Zuclopenthixol—ADRA2A—female reproductive system—breast cancer	4.57e-05	0.0223	CbGeAlD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—breast cancer	4.57e-05	0.000131	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—breast cancer	4.55e-05	0.000131	CcSEcCtD
Zuclopenthixol—HRH1—adrenal gland—breast cancer	4.54e-05	0.0221	CbGeAlD
Zuclopenthixol—Decreased appetite—Doxorubicin—breast cancer	4.49e-05	0.000129	CcSEcCtD
Zuclopenthixol—ADRA2A—adrenal gland—breast cancer	4.46e-05	0.0217	CbGeAlD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—breast cancer	4.46e-05	0.000128	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—breast cancer	4.45e-05	0.000128	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—breast cancer	4.42e-05	0.000127	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—breast cancer	4.42e-05	0.000127	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—breast cancer	4.41e-05	0.000127	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—breast cancer	4.41e-05	0.000127	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—breast cancer	4.4e-05	0.000126	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—breast cancer	4.28e-05	0.000123	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—breast cancer	4.26e-05	0.000122	CcSEcCtD
Zuclopenthixol—HTR2A—pituitary gland—breast cancer	4.25e-05	0.0207	CbGeAlD
Zuclopenthixol—HRH1—female gonad—breast cancer	4.23e-05	0.0206	CbGeAlD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—breast cancer	4.23e-05	0.000121	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—breast cancer	4.22e-05	0.000121	CcSEcCtD
Zuclopenthixol—ADRA2A—female gonad—breast cancer	4.16e-05	0.0202	CbGeAlD
Zuclopenthixol—Hypersensitivity—Epirubicin—breast cancer	4.11e-05	0.000118	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—breast cancer	4.08e-05	0.000117	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—breast cancer	4.08e-05	0.000117	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—breast cancer	4.08e-05	0.000117	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—breast cancer	4.01e-05	0.000115	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—breast cancer	3.95e-05	0.000114	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—breast cancer	3.95e-05	0.000113	CcSEcCtD
Zuclopenthixol—HRH1—endocrine gland—breast cancer	3.94e-05	0.0192	CbGeAlD
Zuclopenthixol—HTR2A—female reproductive system—breast cancer	3.89e-05	0.0189	CbGeAlD
Zuclopenthixol—ADRA2A—endocrine gland—breast cancer	3.87e-05	0.0188	CbGeAlD
Zuclopenthixol—Diarrhoea—Epirubicin—breast cancer	3.82e-05	0.00011	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—breast cancer	3.81e-05	0.000109	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—breast cancer	3.79e-05	0.000109	CcSEcCtD
Zuclopenthixol—HTR2A—adrenal gland—breast cancer	3.79e-05	0.0185	CbGeAlD
Zuclopenthixol—Rash—Methotrexate—breast cancer	3.76e-05	0.000108	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—breast cancer	3.76e-05	0.000108	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—breast cancer	3.74e-05	0.000107	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—breast cancer	3.71e-05	0.000107	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—breast cancer	3.69e-05	0.000106	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—breast cancer	3.66e-05	0.000105	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—breast cancer	3.55e-05	0.000102	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—breast cancer	3.54e-05	0.000102	CcSEcCtD
Zuclopenthixol—CYP2D6—female reproductive system—breast cancer	3.54e-05	0.0172	CbGeAlD
Zuclopenthixol—Diarrhoea—Doxorubicin—breast cancer	3.54e-05	0.000102	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—breast cancer	3.52e-05	0.000101	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—breast cancer	3.52e-05	0.000101	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—breast cancer	3.5e-05	0.000101	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—breast cancer	3.42e-05	9.82e-05	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—breast cancer	3.32e-05	9.54e-05	CcSEcCtD
Zuclopenthixol—HTR2A—endocrine gland—breast cancer	3.29e-05	0.016	CbGeAlD
Zuclopenthixol—Vomiting—Doxorubicin—breast cancer	3.29e-05	9.44e-05	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—breast cancer	3.26e-05	9.37e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—breast cancer	3.26e-05	9.36e-05	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—breast cancer	3.24e-05	9.31e-05	CcSEcCtD
Zuclopenthixol—CYP2D6—female gonad—breast cancer	3.22e-05	0.0157	CbGeAlD
Zuclopenthixol—Nausea—Doxorubicin—breast cancer	3.07e-05	8.82e-05	CcSEcCtD
Zuclopenthixol—CYP2D6—endocrine gland—breast cancer	3e-05	0.0146	CbGeAlD
Zuclopenthixol—HRH1—lymph node—breast cancer	2.72e-05	0.0133	CbGeAlD
Zuclopenthixol—ADRA2A—lymph node—breast cancer	2.67e-05	0.013	CbGeAlD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—breast cancer	5.65e-06	5.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—breast cancer	5.65e-06	5.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	5.61e-06	5.5e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK3—breast cancer	5.61e-06	5.5e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—breast cancer	5.6e-06	5.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—breast cancer	5.57e-06	5.46e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—breast cancer	5.56e-06	5.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—breast cancer	5.55e-06	5.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—breast cancer	5.54e-06	5.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK8—breast cancer	5.53e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	5.52e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	5.52e-06	5.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—breast cancer	5.51e-06	5.4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—breast cancer	5.51e-06	5.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—breast cancer	5.51e-06	5.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—breast cancer	5.5e-06	5.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	5.46e-06	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—breast cancer	5.45e-06	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—breast cancer	5.45e-06	5.35e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—breast cancer	5.44e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—breast cancer	5.44e-06	5.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—breast cancer	5.42e-06	5.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	5.4e-06	5.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	5.4e-06	5.29e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—breast cancer	5.35e-06	5.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—breast cancer	5.35e-06	5.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—breast cancer	5.34e-06	5.24e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—breast cancer	5.33e-06	5.23e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—breast cancer	5.31e-06	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—breast cancer	5.28e-06	5.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—breast cancer	5.28e-06	5.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT2—breast cancer	5.28e-06	5.17e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—breast cancer	5.26e-06	5.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—breast cancer	5.25e-06	5.15e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—breast cancer	5.25e-06	5.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—breast cancer	5.24e-06	5.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—breast cancer	5.24e-06	5.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—breast cancer	5.15e-06	5.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—breast cancer	5.1e-06	5e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—breast cancer	5.09e-06	4.99e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MDM2—breast cancer	5.07e-06	4.97e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	5.07e-06	4.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RAF1—breast cancer	5.06e-06	4.96e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—breast cancer	5.05e-06	4.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—breast cancer	5.04e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RELA—breast cancer	5.03e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	5.02e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	5.01e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	5.01e-06	4.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—breast cancer	5e-06	4.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—breast cancer	5e-06	4.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MDM2—breast cancer	4.99e-06	4.89e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MDM2—breast cancer	4.98e-06	4.88e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RAF1—breast cancer	4.97e-06	4.88e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RAF1—breast cancer	4.96e-06	4.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—breast cancer	4.96e-06	4.87e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RELA—breast cancer	4.95e-06	4.86e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RELA—breast cancer	4.94e-06	4.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—breast cancer	4.94e-06	4.84e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MTOR—breast cancer	4.94e-06	4.84e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAV1—breast cancer	4.93e-06	4.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—breast cancer	4.92e-06	4.83e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—breast cancer	4.91e-06	4.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	4.91e-06	4.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—breast cancer	4.9e-06	4.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MDM2—breast cancer	4.89e-06	4.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RAF1—breast cancer	4.87e-06	4.78e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—breast cancer	4.86e-06	4.76e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MTOR—breast cancer	4.86e-06	4.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RELA—breast cancer	4.85e-06	4.76e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—breast cancer	4.85e-06	4.75e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MTOR—breast cancer	4.85e-06	4.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK3—breast cancer	4.83e-06	4.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—breast cancer	4.82e-06	4.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—breast cancer	4.79e-06	4.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	4.76e-06	4.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MTOR—breast cancer	4.76e-06	4.66e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—breast cancer	4.74e-06	4.65e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—breast cancer	4.71e-06	4.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—breast cancer	4.69e-06	4.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—breast cancer	4.68e-06	4.59e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—breast cancer	4.67e-06	4.58e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—breast cancer	4.66e-06	4.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—breast cancer	4.64e-06	4.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—breast cancer	4.63e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—breast cancer	4.63e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—breast cancer	4.63e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—breast cancer	4.59e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—breast cancer	4.58e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—breast cancer	4.57e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—breast cancer	4.57e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	4.56e-06	4.47e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—breast cancer	4.56e-06	4.47e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—breast cancer	4.55e-06	4.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MDM2—breast cancer	4.54e-06	4.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—breast cancer	4.54e-06	4.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—breast cancer	4.54e-06	4.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—breast cancer	4.53e-06	4.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RAF1—breast cancer	4.53e-06	4.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—breast cancer	4.51e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—breast cancer	4.51e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RELA—breast cancer	4.51e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—breast cancer	4.5e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—breast cancer	4.49e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—breast cancer	4.48e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—breast cancer	4.48e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—breast cancer	4.47e-06	4.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	4.46e-06	4.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—breast cancer	4.46e-06	4.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—breast cancer	4.46e-06	4.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—breast cancer	4.45e-06	4.36e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—breast cancer	4.44e-06	4.35e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—breast cancer	4.43e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—breast cancer	4.42e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MTOR—breast cancer	4.42e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	4.42e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	4.41e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—breast cancer	4.41e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNB1—breast cancer	4.38e-06	4.29e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—breast cancer	4.37e-06	4.29e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—breast cancer	4.37e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—breast cancer	4.35e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—breast cancer	4.35e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—breast cancer	4.34e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—breast cancer	4.34e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—breast cancer	4.34e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—breast cancer	4.33e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNB1—breast cancer	4.31e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNB1—breast cancer	4.3e-06	4.21e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—breast cancer	4.29e-06	4.21e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—breast cancer	4.28e-06	4.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—breast cancer	4.27e-06	4.19e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—breast cancer	4.26e-06	4.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—breast cancer	4.26e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—breast cancer	4.25e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—breast cancer	4.25e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—breast cancer	4.22e-06	4.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—breast cancer	4.22e-06	4.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	4.22e-06	4.13e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—breast cancer	4.21e-06	4.13e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—breast cancer	4.21e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—breast cancer	4.2e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—breast cancer	4.2e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—breast cancer	4.19e-06	4.11e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK8—breast cancer	4.17e-06	4.09e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—breast cancer	4.16e-06	4.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	4.15e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—breast cancer	4.13e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	4.12e-06	4.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—breast cancer	4.11e-06	4.03e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK8—breast cancer	4.11e-06	4.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	4.1e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—breast cancer	4.1e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK8—breast cancer	4.1e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—breast cancer	4.09e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—breast cancer	4.09e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—breast cancer	4.06e-06	3.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—breast cancer	4.06e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—breast cancer	4.04e-06	3.96e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK8—breast cancer	4.02e-06	3.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—breast cancer	4.01e-06	3.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—breast cancer	3.99e-06	3.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—breast cancer	3.96e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—breast cancer	3.96e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—breast cancer	3.95e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—breast cancer	3.95e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	3.92e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—breast cancer	3.9e-06	3.82e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—breast cancer	3.89e-06	3.82e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—breast cancer	3.88e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—breast cancer	3.86e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—breast cancer	3.85e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—breast cancer	3.84e-06	3.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	3.83e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—breast cancer	3.82e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—breast cancer	3.81e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—breast cancer	3.81e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—breast cancer	3.79e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—breast cancer	3.78e-06	3.71e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—breast cancer	3.78e-06	3.71e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—breast cancer	3.75e-06	3.68e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—breast cancer	3.74e-06	3.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK8—breast cancer	3.73e-06	3.66e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—breast cancer	3.73e-06	3.66e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—breast cancer	3.72e-06	3.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—breast cancer	3.71e-06	3.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—breast cancer	3.69e-06	3.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—breast cancer	3.67e-06	3.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK3—breast cancer	3.64e-06	3.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK3—breast cancer	3.59e-06	3.52e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK3—breast cancer	3.58e-06	3.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—breast cancer	3.54e-06	3.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—breast cancer	3.54e-06	3.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—breast cancer	3.54e-06	3.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—breast cancer	3.53e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK3—breast cancer	3.51e-06	3.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—breast cancer	3.49e-06	3.42e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—breast cancer	3.48e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—breast cancer	3.48e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—breast cancer	3.47e-06	3.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—breast cancer	3.47e-06	3.4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.45e-06	3.38e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—breast cancer	3.44e-06	3.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—breast cancer	3.41e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.41e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—breast cancer	3.41e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—breast cancer	3.41e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—breast cancer	3.41e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—breast cancer	3.4e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.34e-06	3.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—breast cancer	3.27e-06	3.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK3—breast cancer	3.26e-06	3.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—breast cancer	3.26e-06	3.19e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—breast cancer	3.22e-06	3.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—breast cancer	3.22e-06	3.16e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—breast cancer	3.22e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—breast cancer	3.17e-06	3.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3.17e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—breast cancer	3.16e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—breast cancer	3.1e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—breast cancer	3.01e-06	2.95e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—breast cancer	2.98e-06	2.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—breast cancer	2.96e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—breast cancer	2.95e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—breast cancer	2.93e-06	2.87e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—breast cancer	2.91e-06	2.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	2.9e-06	2.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—breast cancer	2.86e-06	2.81e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—breast cancer	2.86e-06	2.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—breast cancer	2.8e-06	2.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—breast cancer	2.78e-06	2.73e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—breast cancer	2.74e-06	2.69e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—breast cancer	2.73e-06	2.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	2.69e-06	2.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—breast cancer	2.68e-06	2.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—breast cancer	2.66e-06	2.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—breast cancer	2.63e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—breast cancer	2.62e-06	2.57e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—breast cancer	2.62e-06	2.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—breast cancer	2.61e-06	2.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—breast cancer	2.57e-06	2.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—breast cancer	2.46e-06	2.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—breast cancer	2.42e-06	2.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—breast cancer	2.41e-06	2.37e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—breast cancer	2.38e-06	2.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.37e-06	2.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.2e-06	2.16e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—breast cancer	2.1e-06	2.06e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—breast cancer	1.71e-06	1.68e-05	CbGpPWpGaD
